Stock AMGN AMGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Amgen Inc.

Equities

AMGN

US0311621009

Real-time Estimate Cboe BZX
Other stock markets
 12:28:14 2024-04-26 pm EDT 		5-day change 1st Jan Change
269.4 USD +0.03% Intraday chart for Amgen Inc. +0.48% -6.18%
05:03pm Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe MT
03:38pm Amgen to Seek European OK of Thyroid Eye Disease Drug Tepezza DJ

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe
MT
Amgen to Seek European OK of Thyroid Eye Disease Drug Tepezza
DJ
AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY
PR
Amgen : How Amgen’s Real-World Evidence Is Changing The Future of Patient Care in Psoriatic Disease
PU
The Pleading Standard For Complex Technology? It's Complex.
AQ
MDL Panel Grants Transfer Of Aflibercept BPCIA Case
AQ
Wall Street: tech and SOXX in free fall this week
CF
Wall Street: tech and SOXX in free fall this week
CF
Amgen : First Cancer Diagnosis Led to a Dark Place—Aiding Another Helped Lift Him Out of It
PU
AMGEN TO PRESENT TEZSPIRE PHASE 2A COPD DATA AT ATS 2024
AQ
UBS Adjusts Amgen's Price Target to $284 From $314, Maintains Neutral Rating
MT
Amgen Plans for Phase 3 Trial of Tezepelumab for Lung Disease
MT
Navigating the Landscape of Precision Medicine in Gastric Cancer: FGFR2b Protein Overexpression as an Emerging Biomarker
PU
TD Cowen Cuts Price Target on Amgen to $360 From $370, Buy Rating Kept
MT
Goldman Sachs Adjusts Amgen Price Target to $359 From $361, Maintains Buy Rating
MT
Neumora's early-stage schizophrenia drug study put on hold
RE
BMO Lowers Price Target on Amgen to $336 From $343
MT
Amgen : CEO Bob Bradway's 2023 Letter to Shareholders
PU
Amgen : Chairman and CEO Letter and Amgen Inc. 2023 Annual Report
PU
Morgan Stanley Raises 2024, 2025 EPS Estimates for Regeneron Pharmaceuticals, Amgen
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AMGN Stock
  4. News Amgen Inc.